Cepheid enters license agreement with DxS Ltd.

By Ted A. Knutson

Washington, Dec. 2 - Cepheid said Friday it entered into a license agreement with DxS Ltd., a private U.K.-based company, in which DXS granted Cepheid a non-exclusive, worldwide, royalty-bearing license to certain DXS patents and other intellectual property rights relating to the detection of nucleic acid amplification.

Under the agreement, Cepheid will be able to use the licensed rights to develop and sell assay products incorporating the licensed technology in the human in vitro diagnostics field.

In exchange, Cepheid agreed to pay an initial license fee and to pay quarterly royalties during the term of the agreement. Cepheid may terminate the agreement for any reason upon 60 days written notice to DxS.

Sunnyvale, Calif.-based Cepheid develops, manufactures, and markets fully integrated systems that perform genetic analysis, including DNA and RNA analysis, for the clinical genetic assessment, biothreat and life sciences markets.

The announcement was made in an 8-K filing with the Securities and Exchange Commission.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.